James C. Katzaroff
James C. Katzaroff is founder, CEO and chairman of Advanced Medical Isotope Corporation. A serial entrepreneur who started his first company importing minerals and pewter from Brazil while in high school in southern California, Mr. Katzaroff is constantly searching for outstanding opportunities. This included meeting and marrying his supportive wife, while earning a Business Economics degree from the University of California at Santa Barbara and coaching a swim team. Hired straight out of college Mr. Katzaroff was a financial consultant for Wall Street firms Bateman Eichler, Smith Barney and EFHutton. Since 1990, he has been responsible for corporate engineering, senior-level corporate strategy, fostering investment bank relationships, and has served as a senior financial advisor for numerous start-ups and development stage companies. A strong desire to make an unshakable impact in the fight against cancer led Mr. Katzaroff to found AMIC in 2006. Currently he is securing powerful financing partners for AMIC expansion and to meet their important goal of providing 50% of the supply of US Mo-99 by 2015.
Dr. Robert E. Schenter
Dr. Robert E. Schenter serves as the Chief Science Officer at AMIC, bringing his 40+ years of expertise in research and development in neutron cross-section and decay. Robert E. Schenter is, and has been (for the last 30 years), a world authority on isotope production. In the United States he is also a leading expert on fission reactor and charged particle accelerator production of isotopes, having served as the Site Director/Deputy Site Director in the Isotope Program Office for Westinghouse Hanford Company (WHC) and Pacific Northwest National Laboratory (PNNL), and as a member of the Nuclear Regulatory Commission (NRC) Advisory Committee on the Medical Use of Isotopes (ACMUI). As the Chief Science Officer (CSO) for Advanced Medical Isotope Corporation (AMIC), Dr. Schenter has worked with a number of student employees performing thousands of calculations focusing on the production of more than 150 different medical isotopes using charged particle accelerators. Most recently, he has been performing analyses on different approaches to produce Molybdenum-99.
Dr. Donald A. Ludwig
Donald A. Ludwig, PhD., is Director of Special Projects for AMIC. As an expert in particle accelerator applications in radiation therapy, nuclear medicine and radioisotope production Dr. Ludwig also serves as an advisor to numerous entities in the field, both domestic and foreign. Among these are the Atomic Energy of Canada, the U. S. Department of Energy Labs at Los Alamos, Berkeley, Fermi, Hanford and Oak Ridge, the Israel Atomic Energy Agency, the Australian Nuclear Science and Technology Organization, the Budker Institute of Nuclear Physics in Novosibirsk, Siberia, the Malaysian Institute of Nuclear Technology and the Bhabha Atomic Research Center in Mumbai, India. He holds advanced degrees in nuclear physics, medical physics and marketing from top tier Universities. Dr. Ludwig’s endeavors for AMIC are focused on facilitating the return of clinical radioisotope production to the US, and aiding AMIC in becoming the largest provider of radioisotopes in North America.
Dr. Nigel R. Stevenson
Dr. Stevenson currently serves in a consultant capacity as the Chief Science Advisor at AMIC. He brings with him an impressive background in isotope production. He began his career as a research scientist at TRIUMF, the Canadian Accelerator Facility, before heading up the Isotope Production and Applied Technology group at TRIUMF responsible for the production of a wide variety of radioactive medical isotopes for Nordion in addition to specialized isotope production technology. In 1999 he became the V.P. of Isotope Production and Research for Theragenics Corporation in Atlanta, GA. In this role he was responsible for installing and operating the world’s largest cyclotron facility (14 machines) used to produce radiochemicals for pharmaceuticals and medical devices. He also had technical oversight of a large scale stable isotope separation facility in Oak Ridge, TN. He was appointed the Chief Operating Officer of Trace Life Sciences, before assuming his current role as Chief Operating Officer of Clear Vascular. Additionally, he is the CEO of TcNet, LLC, a company that is investigating the use of PET cyclotron systems to produce a number of additional radiochemicals. Dr. Stevenson obtained his Ph.D. at the University Of London, UK in 1983 in Nuclear Physics.
Dr. Alan E. Waltar
Dr. Alan E. Waltar serves as Chair of the Scientific Committee for AMIC, having recently retired as Director of Nuclear Energy at the Pacific Northwest National Laboratory (PNNL). He has also served as Head of the Nuclear Engineering Department for Texas A&M and President of the American Nuclear Society. He holds a PhD in Engineering Science from the UC, Berkeley. Dr. Waltar served in numerous engineering and management roles in his 30-year career with Westinghouse Hanford Company. He was instrumental in the formation of the World Nuclear University (WNU) Summer Institute (SI) and has served as a mentor, lecturer, and MC for all six of the SIs to date—as well as the WNU Radioisotopes School in Korea (2010). Additionally, he led a People-to-People Ambassadors Nuclear Delegation to China in October 2007 and India in 2009. Dr. Waltar currently serves as a consultant to numerous governmental national and international nuclear organizations as well as several private nuclear firms. His support for AMIC is focused on helping the company meet their goals of efficient, broad spectrum, domestic radioisotope production.
Dr. Fu Min Su
Fu Min Su, Ph.D., is AMIC's Chief Radio-Chemist and Radiation Safety Officer. Having received his Ph.D. from the University of Washington, he has authored a number of scientific papers and written numerous abstracts for the Journal of Nuclear Medicine. Dr Su also holds several patents relating to radionuclide production and preparation. With over 20 years experience in medical isotope R&D and manufacture, Dr. Su is also an expert in the area of coordinating and conducting clinical trials. Working as a senior scientist for several bio-technology firms, including NeoRx, Nycomed-Amersham, Bristol-Myers Squibb, and Cellectar, he developed various radiopharmaceuticals, isotope production methods and generator systems. Dr Su is currently supervising F-18 FDG production at AMIC’s lab using a compact proton linear accelerator.
Leonard Bruce Jolliff
Leonard Bruce Jolliff, joined Advanced Medical Isotope Corporation as Chief Financial Officer in 2006. For nine years prior to joining the Company, Mr. Jolliff was a sole practitioner in the role of CFO for Hire and as a Forensic Accountant, working with companies ranging from Fortune 500 to small family operations. Mr. Jolliff is a CPA and a member of the Washington Society of CPAs. He is also a Certified Fraud Examiner and a member of the Association of Certified Fraud Examiners. Mr. Jolliff has held CFO and Controller positions in an array of industries and has worked as a CPA in public practice. Currently all of Mr. Jolliff’s energy is focused on supporting AMIC’s isotope production and securing new investments which will enable the growing company to meet it’s goals.
Dr. Mike Korenko
Mike Korenko is advisor to the board for AMIC and is also responsible for new product development. He was the Westinghouse VP in charge of the 300 and 400 areas and all the engineering, safety analysis, and projects for the Hanford site, and the EVP of Closure for Safe Sites of Colorado at Rocky Flats. He is the co-inventor of the new disclosure to convert nuclear waste to medical isotopes. He is currently President of Kor Ideas. Mr. Korenko has a Doctor of Science from MIT and was a NATO Postdoctoral Fellow at Oxford University. He was selected as a White House Fellow for the Department of Defense reporting to Secretary Cap Weinberger. He has 28 patents and has received many awards including the National Energy Resources Organization Research and Development Award. Mr. Korenko’s personal goal for AMIC is to expand the company’s profitability via brachytherapy seeds and Moly-99 production.
Marishka Pilch
As Marketing Director at AMIC, Marishka Pilch is involved with corporate communications on many levels, including website upkeep, creating investor presentations, and coordinating tradeshows. Her extensive healthcare, sales and marketing experience allow her to help make the AMIC message more accessible. In 2004, she founded PET2Market, a consulting firm specializing in marketing and clinical education for Positron Emission Tomography imaging centers. Prior positions for Pilch included marketing and client support at Alliance Imaging, a national provider of diagnostic imaging services. Ms. Pilch believes AMIC initiatives have the potential to positively impact millions of lives. Her goal is to make AMIC a household name.
Cleta Mayfield
Cleta Mayfield has worked as the office administrator and sales coordinator at AMIC for three years. Before joining the team at AMIC, she served as the finance director for the Girl Scouts of America. Cleta has a great business savvy, and an understanding of “high touch” customer service, as she and her husband own several successful businesses in Washington and Oregon. Cleta works to ensure the efficient running of the AMIC production center, and in so doing, further the company's goals in nuclear medicine.